Preventive strategies in chronic liver disease: part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise.

Chronic liver disease is the 10th leading cause of death in the United States. Hepatitis C virus infection is the most frequent cause of chronic liver disease and the most common indication for liver transplantation. Preventive care can significantly reduce the progression of liver disease. Alcohol and hepatitis C virus are synergistic in hastening the development of cirrhosis; therefore, patients with hepatitis C infection should abstain from alcohol use. Because superinfection with hepatitis A or B virus can lead to liver failure, vaccination is recommended. Potentially hepatotoxic medications should be used with caution in patients with chronic liver disease. In general, nonsteroidal anti-inflammatory drugs should be avoided; acetaminophen in a dosage below 2 g per day is the safest choice. Many herbal remedies are potentially hepatotoxic, and only milk thistle can be used safely in patients who have chronic liver disease. Weight reduction and exercise can improve liver function in patients with fatty liver.

[1]  B. Balkau,et al.  A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. , 1991, The New England journal of medicine.

[2]  K. Reddy,et al.  Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy , 1996, Annals of Internal Medicine.

[3]  P. O'Connor,et al.  Patients with alcohol problems. , 1998, The New England journal of medicine.

[4]  W. Schaffner,et al.  Adult Immunizations , 1996, Annals of Internal Medicine.

[5]  H. Zimmerman,et al.  Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure , 1995, Hepatology.

[6]  E. Schiff,et al.  Hepatitis C and Alcohol , 2003, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.

[7]  B. McMahon,et al.  Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease , 1998, Hepatology.

[8]  W. Irish,et al.  Response to interferon α therapy is influenced by the iron content of the liver , 1994 .

[9]  D. V. van Thiel,et al.  Response to interferon alpha therapy is influenced by the iron content of the liver. , 1994, Journal of hepatology.

[10]  Lewis Jh,et al.  Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. , 1995 .

[11]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[12]  E. Keeffe.  Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? , 1995, The American journal of gastroenterology.

[13]  D. Francis.  The public's health unprotected. Reversing a decade of underutilization of hepatitis B vaccine. , 1995, JAMA.

[14]  Jill P. Smith,et al.  Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis c: a case series , 1998, American Journal of Gastroenterology.

[15]  K. Reddy,et al.  Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. , 1996, Annals of internal medicine.

[16]  Alan D. Lopez,et al.  Alcohol consumption and mortality among middle-aged and elderly U.S. adults. , 1997, The New England journal of medicine.

[17]  M. Friedman,et al.  Relationship between liver biochemical tests and dietary intake in patients with liver disease. , 1994, Journal of clinical gastroenterology.

[18]  G. Davis.  Combination treatment with interferon and ribavirin for chronic hepatitis C. , 1999, Clinics in liver disease.

[19]  S. Vento,et al.  Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C , 2000, Journal of viral hepatitis.

[20]  S. L. Murphy.  Deaths: final data for 1998. , 2000, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[21]  K. Tanikawa,et al.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.

[22]  E. Schiff,et al.  Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. , 1995, Gastroenterology.

[23]  M A Gerber,et al.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. , 1992, The New England journal of medicine.

[24]  G. Corrao,et al.  Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. , 1998, Hepatology.

[25]  L. Gallagher.  Hepatitis B. , 2016, Journal.

[26]  P. Schirmacher,et al.  Viral and host factors in the prediction of response to interferon‐α therapy in chronic hepatitis C after long‐term follow‐up , 1998, Journal of viral hepatitis.

[27]  Miriam J. Alter.  Epidemiology of hepatitis C. , 1996 .

[28]  O. Senofonte,et al.  Iron overload in patients with chronic viral hepatitis: how common is it? , 1997, The American journal of gastroenterology.

[29]  H. Rosen,et al.  Milk Thistle (Silybum marianum) for the Therapy of Liver Disease , 1998, American Journal of Gastroenterology.

[30]  R. Scheig.  Effects of ethanol on the liver. , 1970, The American journal of clinical nutrition.

[31]  R. Steele.  Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. , 1998, Clinical pediatrics.

[32]  B. Bell.  Hepatitis A vaccine. , 2002, Seminars in pediatric infectious diseases.

[33]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[34]  A. McCullough,et al.  Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology , 1998, American Journal of Gastroenterology.

[35]  M. Yano,et al.  Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. , 1994, The American journal of gastroenterology.

[36]  L. Jeffers,et al.  Hepatitis C and alcohol. , 1999, Alcoholism, clinical and experimental research.

[37]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[38]  J. Hoofnagle,et al.  Measurements of iron status in patients with chronic hepatitis. , 1992, Gastroenterology.

[39]  J. Carson,et al.  Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence. , 1993, Drugs.